Liquid chromatography-tandem mass spectrometry method for detecting colloidal fiber acidic protein in human cerebrospinal fluid
Through liquid chromatography tandem mass spectrometry technology and trypsin digestion, the problem of inconsistency in GFAP detection results was solved, and the accurate quantitative detection of GFAP in human cerebrospinal fluid was achieved, and the standardization and clinical application of GFAP detection was promoted.
Patent Information
- Application Number
- CN202411102191.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-12-03
AI Technical Summary
The existing GFAP detection methods have problems that inconsistency and accuracy of detection results are difficult to guarantee, especially among testing platforms of different laboratories and reagent manufacturers, which makes it difficult to establish a unified diagnostic cut-point value, limiting GFAP in AD diagnosis and Application in treatment.
Using liquid chromatography tandem mass spectrometry (LC-MS/MS) technology, a GFAP characteristic peptide such as SVSEGHLK was detected, combined with trypsin cleavage and isotope internal standard method, a GFAP used in human cerebrospinal fluid was established. Accurate quantitative analysis methods, including specific chromatographic separation and mass spectrometry conditions, ensure the accuracy and consistency of detection.
It realizes accurate and reliable quantitative detection of GFAP in human cerebrospinal fluid, promotes the consistency and standardization of GFAP detection, improves the reliability and consistency of detection results, and helps promote GFAP in clinical applications.
Smart Images

Figure CN119064491A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical detection technology, and in particular to a liquid chromatography-tandem mass spectrometry method for detecting glial fibrillary acid protein in human cerebrospinal fluid. Background Art
[0002] With the advancement of the global population aging process, my country has rapidly entered a deeply aging society, and the prevalence of dementia is increasing day by day. At present, dementia has become the fifth leading cause of death and the fourth largest "killer" threatening the health of the elderly. Alzheimer's disease (AD), as the most common type of dementia, accounts for 60% to 80% of all dementia populations, with high prevalence, high mortality, and heavy medical burden. Because there is still a lack of effective cure methods, promoting early, accurate diagnosis and timely, precise intervention of AD is of great significance for patient management and the development of new drugs. With the continuous updating and development of clinical guidelines, the clinical manifestations of AD are distinguished from the underlying etiological concepts, and people gradually realize the importance of defining AD through biological concepts and classifying AD through biomarkers. The 2018 International NIA-AA Guidelines proposed a framework of biomarkers with important value for AD diagnosis, namely the "ATX(N)" framework; in the latest version of the NIA-AA guidelines released in 2024, the "X" markers are expanded to "I", "V", and "S". Among them, "V" and "S" are used to identify AD comorbid pathology; while "I" is involved in the occurrence and development of AD and can be used for AD staging, prognosis and efficacy monitoring. "I" refers to inflammatory markers, and the representative indicators are glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and peripheral blood.
[0003] GFAP is an intermediate filament structural protein involved in cytoskeleton assembly and integrity, and is highly expressed in activated glial cells. As a marker of inflammation and astrocyte activation, GFAP has been used in the past for early identification and auxiliary diagnosis of central nervous system diseases such as traumatic brain injury and multiple sclerosis. In the past decade, the application value of CSF and peripheral blood GFAP in AD has been gradually discovered and has received more and more research and attention, mainly including early diagnosis, disease prognosis and efficacy monitoring. At present, the main detection method for CSF and peripheral blood GFAP is SIMOA technology; Lumipulse and Roche Elecsys fully automatic chemiluminescence immunoassay systems have developed GFAP detection kits, but they are still in the original research state; in China, United Biotech Co., Ltd. has developed a serum GFAP detection kit, which has been approved by the Beijing Municipal Drug Administration. However, there are significant differences in the concentration levels of CSF and / or peripheral blood GFAP measured by different detection platforms reported in different studies. The differences in the binding sites and affinities of antibodies used by different reagent manufacturers for GFAP may be the reason for the great differences in the detection results between different detection methods. In addition, even if the same detection platform is used, such as the most commonly used SIMOA detection platform, there are significant differences in the levels of GFAP reported by different research institutes, and the differences can reach orders of magnitude, indicating that the consistency of the test results is poor. It can be seen that the accuracy of GFAP determination in different laboratories is difficult to guarantee and a unified diagnostic cut-off value is difficult to establish. These factors greatly limit the further clinical application and development of GFAP. Liquid chromatography–tandem mass spectrometry (LC–MS / MS) technology is an important technical means to achieve accurate determination of biomarkers and promote detection consistency and standardization, but no LC–MS / MS method that can be used for accurate quantification of GFAP has been found so far.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a liquid chromatography tandem mass spectrometry method for detecting glial fibrillary acid protein in human cerebrospinal fluid.
[0006] Specifically, the technical solution of the present invention is as follows: The invention provides a liquid chromatography tandem mass spectrometry method for detecting glial fibrillary acid protein in human cerebrospinal fluid, which comprises detecting a GFAP characteristic peptide segment by mass spectrometry; the GFAP characteristic peptide segment is selected from: DNLAQDLATVR, EAASYQEALAR and SVSEGHLK.
[0007] Preferably, the GFAP characteristic peptide segment is SVSEGHLK; and the chromatographic column is ACQUIYT UPLC PremierHSS T3 chromatographic column.
[0008] Preferably, the chromatographic separation conditions of the characteristic peptide segment SVSEGHLK include: Column temperature: 45±5℃; Mobile phase A: 0.001±0.0002% formic acid in water; Mobile phase B: methanol; Mobile phase flow rate: 0.30±0.05 mL / min.
[0009] Preferably, the chromatographic separation conditions of the characteristic peptide segment SVSEGHLK also include the following elution procedure: 0.0~1.0 min, mobile phase A: 100%~100%; 1.0-6.9 min, mobile phase A: 100%-90%; 6.9-7.4 min, mobile phase A: 90%-20%; 7.4-8.3 min, mobile phase A: 20%-20%; 8.3-8.4 min, mobile phase A: 20-100%; 8.4~9.0 min, mobile phase A: 100~100%.
[0010] Preferably, the GFAP characteristic peptide segment is SVSEGHLK; the parent ion of the detection signal generated by the characteristic peptide segment SVSEGHLK in the mass spectrometer has a mass-to-charge ratio of 428.6~428.8; it contains daughter ions with mass-to-charge ratios of 454.2~454.4 and 670.3~670.5; the cone voltage is 28.0±0.5 V; and the collision energy is 16.5±2.0 eV.
[0011] Preferably, 15 The N-labeled GFAP full-length protein was used as the internal standard. The parent ion of the peptide generated by the internal standard after enzyme cleavage in the mass spectrometer had a mass-to-charge ratio of 434.1-434.3; it contained product ions with mass-to-charge ratios of 461.2-461.4 and 679.2-679.4; the cone voltage was 24.0±0.5 V; and the collision energy was 14.0±0.5 eV.
[0012] Preferably, the mass spectrometry conditions also include: using an electrospray ion source, multiple reaction monitoring mode; the capillary voltage is 2.00±0.05 kV; the desolvation gas temperature is 600±10°C; the desolvation gas flow is 1200±20 L / Hr; the cone gas flow is 150±5 L / Hr; and the nebulizer gas flow is 7.0±0.5 Bar.
[0013] Preferably, the liquid chromatography tandem mass spectrometry method comprises the following steps: heating the CSF sample for denaturation for 5-15 minutes, adding a stable isotope internal standard after cooling to room temperature and mixing, drying with nitrogen and then adding trypsin for enzymatic digestion, and then performing liquid chromatography tandem mass spectrometry detection on the enriched enzymatic digestion sample.
[0014] Preferably, the liquid chromatography tandem mass spectrometry method further comprises the following steps: drawing a standard curve according to the concentration of the standard solution and the detected signal intensity; replacing the standard solution with the sample to be tested and detecting it in the same manner; obtaining the concentration of the characteristic peptide segment in the sample to be tested according to the detection result of the sample to be tested and comparing it with the standard curve, thereby achieving quantitative detection of GFAP in the sample.
[0015] Preferably, the amount of CSF sample used is 100-200 μL.
[0016] Beneficial effects: The present invention provides a liquid chromatography tandem mass spectrometry method for detecting glial fibrillary acidic protein in human cerebrospinal fluid. The method screens out specific characteristic peptides (such as SVSEGHLK) from GFAP protein for quantitative analysis of CSF GFAP, and the results are accurate and reliable. In addition, the present invention also provides chromatographic conditions that can achieve interference separation and accurate determination, as well as a pre-treatment extraction process for CSFGFAP, which is conducive to the promotion of GFAP detection consistency and standardization. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.
[0018] Figure 1 This is the recommended pre-processing process for CSF GFAP detection in Example 1 of the present invention.
[0019] Figure 2 This is the result of investigating the trypsin cleavage time of GFAP in Example 1 of the present invention.
[0020] Figure 3 This is a representative peak diagram of the quantitative ion pairs of CSF GFAP compounds determined by the LC-MS / MS method in Example 1 of the present invention.
[0021] Figure 4 This is a linear graph of CSF GFAP measured by the LC-MS / MS method in Example 1 of the present invention. DETAILED DESCRIPTION
[0022] At present, no previous studies have been found to accurately quantify GFAP in human CSF and / or peripheral blood using LC–MS / MS technology. It is more difficult to establish an LC–MS / MS method for determining GFAP-like macromolecular proteins than for small molecular compounds. The main method currently used to determine CSF GFAP is Quanterix SIMOA technology; in addition, a small number of studies have used the original research kit or ELISA kit of the Roche Elecsys fully automatic chemiluminescence immunoassay system for determination. The source of the standard and quality control products in the Quanterix SIMOA technology GFAP determination kit is the same, and there is no clear traceability, so the difference between batches of the kit cannot be effectively monitored through the test results of the quality control products. In addition, previous research reports and the early use of this detection platform by our team have found that the test results of different batches of kits vary greatly, up to 10 times. Therefore, the absolute concentration of GFAP quantified by SIMOA technology varies greatly, and the accuracy and reliability of the test results and the consistency of the test results between different batches cannot be guaranteed. In addition, there are significant differences between the test results of different immunological methods, which may be related to the differences in antibody recognition sites and capture efficiency. Therefore, the concentration ranges of CSF GFAP reported in previous studies vary greatly, and there is a lack of a unified reference range and / or cut-off value.
[0023] The technical problem to be solved by the present invention is to establish an LC-MS / MS method that can accurately measure CSF GFAP, in order to promote the consistency of CSF GFAP determination in different laboratories.
[0024] The determination scheme provided by the present invention mainly comprises: using trypsin for enzymatic digestion, using a PRiME HLB 96-well SPE plate for extraction and enrichment of the analyte, and using an isotope internal standard method based on the specific mass / charge ratio (mass-to-charge ratio) generated by electrospray ionization to achieve accurate quantification of CSF GFAP.
[0025] In a more specific preferred embodiment provided by the present invention, the determination method mainly includes the following contents.
[0026] (1) Source of standard products
[0027] Since no GFAP standard and internal standard were found on websites such as Sigma and rPeptide, and the recombinant antigen (HyTest Ltd., Turku, Finland; Cat.#: 8G45) used in the kits of mainstream manufacturers such as QuanterixSIMOA, banyan, and Abbott is a GFAP fragment of amino acids 60 to 383 rather than a full-length protein, which may have different properties from the full-length GFAP protein in the CSF sample during the pre-treatment process, and the number of quantitative peptides available is even smaller, therefore, the standard and internal standard of the full-length GFAP protein used in the present invention are 15 The internal standards of N-labeled GFAP full-length protein were synthesized by Mike Biotech Co., Ltd. (Sichuan Province, China). The GFAP full-length protein contains 432 amino acids, and its amino acid sequence can be obtained from official websites such as UniProt (https: / / www.uniprot.org / ), which is MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLD LERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQM REQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM (SEQ ID NO.1).
[0028] (2) Preparation of standard solution and internal standard solution
[0029] GFAP standards and their 15All N-labeled internal standards were lyophilized powders with a specification of 0.7 mg / bottle. They were fully dissolved in 1 mL of distilled water to obtain a 0.7 mg / mL standard solution. The standard and internal standard solutions were diluted to 0.1 mg / mL and 10 μg / mL using a 40-60% methanol aqueous solution containing 0.5-2.0 mg / mL bovine serum albumin (BSA) and stored at -80 °C. The standard solution was further diluted to 5 μg / mL using a 40-60% methanol aqueous solution containing 0.5-2.0 mg / mL BSA and stored at -20 °C for the preparation of the reserve standard curve; the internal standard solution was diluted to 1 μg / mL and stored in aliquots at -20 °C for future use. For proteins and peptides, adding BSA to the dilution solution can competitively inhibit nonspecific adsorption.
[0030] (3) Mass spectrometry conditions
[0031] Based on the characteristics of the compound, an electrospray ion source was selected, and mass spectrometry analysis was performed based on the multiple reaction monitoring mode. The GFAP protein has a full length of 432 amino acids. The upper limit of the mass-to-charge ratio that can be detected by the triple quadrupole mass spectrometer selected in the present invention is 2048. The full-length protein cannot be directly measured. It needs to be cut into peptide segments by protease, and characteristic peptide segments are selected for detection to characterize the protein concentration. The present invention selects trypsin to digest the GFAP full-length protein standard, selects peptides with a length of about 8 to 15 amino acids, and identifies 22 peptides that meet the requirements, of which 9 peptides are GFAP-specific peptides, namely VDFSLAGALNAGFK (SEQ ID NO.2), LDQLTANSAR (SEQ ID NO.3), DNLAQDLATVR (SEQ ID NO.4), LEAENNLAAYR (SEQ ID NO.5), QEADEATLAR (SEQ ID NO.6), QQVHVELDVAK (SEQ ID NO.7), EAASYQEALAR (SEQ ID NO.8), ITIPVQTFSNLQIR (SEQ ID NO.9) and SVSEGHLK (SEQ ID NO.10). Among them, 6 peptides were discarded due to non-unique peaks and / or too low responses. Three peptides, DNLAQDLATVR, EAASYQEALAR and SVSEGHLK, were initially retained. Combined with the sample pretreatment process, it was found that the main characteristic peptide that can be used for CSF GFAP quantification is SVSEGHLK (abbreviated as SVS).
[0032] (4) Chromatographic conditions
[0033] The peptide segment finally determined by the present invention to be used for quantification of GFAP in CSF samples is mainly the SVS peptide segment, which has a large polarity and is difficult to retain. The present invention selects a T3 chromatographic column. The optimal pH range of the T3 chromatographic column is 2 to 8. The A phase finally selected by the present invention is 0.0001 to 0.01% formic acid water and the B phase is pure methanol. The SVS peptide segment is difficult to retain on the chromatographic column. The initial ratio of the mobile phase gradient is 95 to 100% of the aqueous phase, and the gradient increases slowly to achieve effective separation from the subsequent interference peaks.
[0034] (5) Pre-treatment conditions
[0035] Accurately pipette 100-200 μL CSF sample, denature the protein at 95°C for 5-15 min on a Bluepard constant temperature shaker, cool to room temperature, add internal standard solution and vortex mix. After drying with nitrogen, add trypsin for digestion, and the digested sample is extracted and enriched by Waters PRiME HLB 96-well SPE plate before being loaded onto the machine.
[0036] The present invention establishes for the first time an LC-MS / MS method that can accurately detect CSF GFAP, and provides characteristic peptides that can be used to characterize GFAP, chromatographic conditions that can achieve interference separation and accurate determination, and a pre-treatment extraction process for CSF GFAP. The sample volume of the method described in the present invention is only 100 μL, the detection speed is fast, and the results are accurate and reliable. It is expected to be transformed into a kit for clinical detection, which will help promote the consistency and standardization of GFAP detection.
[0037] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0038] The endpoints and any values of the ranges disclosed in this specification are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0039] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementations", or "some specific implementations" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0040] In the examples provided in this specification, if no specific techniques or conditions are specified, the techniques or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.
[0041] Example 1
[0042] 1. Instruments and consumables
[0043] The LC–MS / MS system used a Waters Acquity I-Class UPLC ultra-high performance liquid chromatograph and a Waters TQ-XS triple quadrupole mass spectrometer (Waters Corp., WAT, USA), and the control software was MassLynx 4.2. An ACQUIYT UPLC Premier HSS T3 column (100Å, 1.8 μm, 2.1 mm × 50 mm) was used for liquid phase separation. Other equipment and consumables included a bluepard constant temperature incubator shaker (Shanghai, China), a Biori metal constant temperature bath (Zhejiang Province, China), a Waters 96-well positive pressure solid phase extraction device, a 700 μL 96-well collection plate, a Waters PRiME HLB 96-well SPE plate, and an Eppendorf 1.5 mL microcentrifuge tube.
[0044] 2. Reagents
[0045] The GFAP standard used in the present invention and 15The internal standard of N-labeled GFAP full-length protein was synthesized by MacBio Co., Ltd. (Sichuan, China). Sequencing-grade trypsin was purchased from Promega (WI, USA); BSA and trifluoroacetic acid were purchased from Sigma (MO, USA); chromatographic-grade methanol, acetonitrile, and formic acid were purchased from Thermo Fisher Scientific (MA, USA); and distilled water was purchased from Watsons (Hong Kong, China).
[0046] 3. Preparation of standard solution and internal standard solution
[0047] GFAP standards and their 15 All N-labeled internal standards were lyophilized powders with a specification of 0.7 mg / bottle. Based on the recommendations of the synthesis manufacturer, 1 mL of distilled water was used to fully dissolve to obtain a 0.7 mg / mL standard solution. The standard and internal standard solutions were diluted to 0.1 mg / mL and 10 μg / mL with a 50% methanol aqueous solution containing 1 mg / mL BSA and stored at -80°C. The standard solution was further diluted to 5 μg / mL with a 50% methanol aqueous solution containing 1 mg / mL BSA and stored at -20°C for the preparation of the reserve standard curve; the internal standard solution was diluted to 1 μg / mL and stored in aliquots at -20°C for later use.
[0048] 4. Pre-treatment
[0049] Accurately aspirate 100 μL of CSF sample, denature the protein at 95°C for 10 minutes on a bluepard constant temperature incubator shaker, cool to room temperature, add 10 μL of internal standard solution and vortex to mix. After drying with nitrogen, add 60 μL of 16μg / mL analytical grade trypsin for overnight digestion. The digested sample is extracted and enriched by a Waters PRiME HLB 96-well SPE plate and then loaded onto the machine. During the establishment of the methodology, the present invention found that the high-temperature denaturation process before digestion has little effect on the quantification of the GFAP protein itself, but the internal standard concentration in the undenatured sample is approximately 60% of the internal standard concentration in the denatured sample, resulting in a different ratio of the compound to the internal standard, affecting the results of accurate quantification and spike recovery. In addition, the present invention also optimizes the conditions for drying / drying the CSF specimen, loading, washing and eluting on the SPE plate, and re-dissolving and loading the machine. The specific pre-treatment schemes used are as follows: Figure 1 shown.
[0050] According to the manufacturer's instructions, the most suitable enzyme cleavage temperature for trypsin is 37 °C. After determining the pretreatment process, the present invention re-evaluated and investigated the enzyme cleavage time based on the highest concentration standard (500 ng / mL) and the mixed CSF sample with the highest concentration standard added. Figure 2As shown in the figure, the complete cleavage of GFAP cannot be achieved even at 37 °C for 8 h, and the sample needs to be treated with enzymes overnight. 15 The internal standard of N-labeled GFAP full-length protein can calibrate the enzyme cleavage process, that is, regardless of whether the enzyme cleavage is complete, the ratio of the response of the analyte and the internal standard is relatively consistent.
[0051] 5. Chromatography
[0052] The present invention selects the preferred column for polar compound analysis—ACQUIYT UPLC Premier HSS T3 chromatographic column, and the column temperature is set to 45°C. Phase A is 0.001% formic acid water, and phase B is pure methanol. The mobile phase flow rate is 0.30 mL / min, and the (phase A) gradient is 0.0~1.0 min: 100%~100%; 1.0~6.9 min: 100%~90%; 6.9~7.4 min: 90%~20%; 7.4~8.3 min: 20%~20%; 8.3~8.4 min: 20~100%; 8.4~9.0min: 100~100%.
[0053] 6. Mass spectrometry
[0054] An electrospray ion source was used, and mass spectrometry analysis was performed based on the multiple reaction monitoring mode. The main quantitative peptide was the SVS peptide, and its ion pairs and corresponding mass spectrometry parameters are shown in Table 1. Other mass spectrometry parameters included: capillary voltage of 2.00 kV, desolvation temperature of 600 °C, desolvation gas flow of 1200 L / Hr, cone gas flow of 150 L / Hr, and nebulizer gas flow of 7.0 Bar.
[0055]
[0056] 7. Test performance and methodological validation results
[0057] (1) Precision verification
[0058] The 5*5 scheme was used for precision evaluation. The repeatability and total imprecision of the LC–MS / MS method for determining CSF GFAP were 5.1%-6.9% and 6.4%-7.9%, respectively, indicating that the method had good precision performance (Table 2).
[0059]
[0060] (2) Correctness verification
[0061] The spiked recoveries of CSF GFAP determined by this LC–MS / MS method ranged from 103.6% to 111.6% ( Table 3 ), which met the method performance requirements.
[0062]
[0063] (3) Sensitivity verification
[0064] The peak time of CSF GFAP determined by the LC–MS / MS method was 6.62 min, and its representative peak diagram is shown in Figure 3 As shown in the figure (quantification limit: A, standard: B, CSF: C), the detection limit is 0.1 ng / mL; the quantification limit is 0.5 ng / mL. A: GFAP quantitative ion pair and its internal standard at the quantification limit (concentration of 0.5 ng / mL); B: GFAP quantitative ion pair and its internal standard at the standard with a concentration of 20.0 ng / mL; C: GFAP quantitative ion pair and its internal standard at the low-value CSF quality control (concentration of 2.56 ng / mL).
[0065] (4) Linear verification
[0066] The theoretical concentration of the standard was taken as the X-axis, the ratio of the peak area of the standard and the internal standard was taken as the Y-axis, and a linear regression fitting was performed with a weight of "1 / X". The LC–MS / MS method showed good linearity in the range of 0.5-500.0 ng / mL for the determination of GFAP ( Figure 4 ), the linear correlation coefficient r>0.995, and the linear range is sufficient to cover the concentration distribution of clinical CSF GFAP.
[0067] (5) Verification of matrix effect
[0068] Six CSF samples with sufficient residual volume from different patients were selected to evaluate the matrix effect of the LC–MS / MS method for the determination of CSF GFAP. Without internal standard correction, some samples had matrix enhancement effects, which could be corrected by the internal standard, as shown in Table 4. After internal standard correction, the matrix effect of GFAP was 91.7%~95.5% when low-level standards were added, and 82.7%~88.6% when high-level standards were added, both within the allowable deviation requirement of 20%.
[0069]
[0070] (6) Carrying pollution
[0071] There is no obvious substance peak in the blank sample after the highest point of the standard curve, which can be considered to have no obvious carryover contamination.
[0072] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A liquid chromatography-tandem mass spectrometry method for detecting glial fibrillary acid protein in human cerebrospinal fluid, characterized in that: The method comprises detecting a characteristic peptide segment of GFAP by mass spectrometry; the characteristic peptide segment of GFAP is selected from: DNLAQDLATVR, EAASYQEALAR and SVSEGHLK.
2. The liquid chromatography tandem mass spectrometry method according to claim 1, characterized in that: The GFAP characteristic peptide segment is SVSEGHLK; the chromatographic column is ACQUIYT UPLC Premier HSS T3 chromatographic column.
3. The liquid chromatography tandem mass spectrometry method according to claim 2, characterized in that: The chromatographic separation conditions of the characteristic peptide SVSEGHLK include: Column temperature: 45±5℃; Mobile phase A: 0.001±0.0002% formic acid in water; Mobile phase B: methanol; Mobile phase flow rate: 0.30±0.05 mL / min.
4. The liquid chromatography tandem mass spectrometry method according to claim 3, characterized in that: The chromatographic separation conditions of the characteristic peptide SVSEGHLK also include the following elution procedure: 0.0~1.0 min, mobile phase A: 100%~100%; 1.0-6.9 min, mobile phase A: 100%-90%; 6.9-7.4 min, mobile phase A: 90%-20%; 7.4-8.3 min, mobile phase A: 20%-20%; 8.3-8.4 min, mobile phase A: 20-100%; 8.4~9.0 min, mobile phase A: 100~100%.
5. The liquid chromatography tandem mass spectrometry method according to claim 1, characterized in that: The characteristic peptide of GFAP is SVSEGHLK; the parent ion of the detection signal generated by the characteristic peptide SVSEGHLK in the mass spectrometer has a mass-to-charge ratio of 428.6-428.8; it contains daughter ions with mass-to-charge ratios of 454.2-454.4 and 670.3-670.5; the cone voltage is 28.0±0.5 V; and the collision energy is 16.5±2.0 eV.
6. The liquid chromatography tandem mass spectrometry method according to claim 5, characterized in that: by 15 The N-labeled GFAP full-length protein was used as the internal standard. The parent ion of the peptide generated by the internal standard after enzyme cleavage in the mass spectrometer had a mass-to-charge ratio of 434.1-434.3; it contained daughter ions with mass-to-charge ratios of 461.2-461.4 and 679.2-679.4; the cone voltage was 24.0±0.5V; and the collision energy was 14.0±0.5 eV.
7. The liquid chromatography tandem mass spectrometry method according to claim 6, characterized in that: The mass spectrometry conditions also include: using an electrospray ion source and multiple reaction monitoring mode; the capillary voltage is 2.00±0.05 kV; the desolvation gas temperature is 600±10℃; the desolvation gas flow is 1200±20 L / Hr; the cone gas flow is 150±5 L / Hr; and the nebulizer gas flow is 7.0±0.5Bar.
8. The liquid chromatography tandem mass spectrometry method according to any one of claims 1 to 7, characterized in that: The method comprises the following steps: heating and denaturing the CSF sample for 5-15 minutes, adding a stable isotope internal standard and mixing after cooling to room temperature, drying with nitrogen and then adding trypsin for enzyme digestion, and then performing liquid chromatography tandem mass spectrometry detection on the enriched enzyme digestion sample.
9. The liquid chromatography tandem mass spectrometry method according to claim 8, characterized in that: The method also includes the following steps: drawing a standard curve according to the concentration of the standard solution and the detected signal intensity; replacing the standard solution with the sample to be tested and using the same method for detection; and obtaining the concentration of the characteristic peptide segment in the sample to be tested according to the detection result of the sample to be tested and comparing with the standard curve, thereby achieving quantitative detection of GFAP in the sample.
10. The liquid chromatography tandem mass spectrometry method according to claim 9, characterized in that: The amount of CSF sample used is 100-200 μL.
